1.Targeted biotherapy for chronic obstructive pulmonary disease
Haodong BAI ; Bingxian SHA ; Yadav Kumar AMBEDKAR ; Xianghuai XU ; Li YU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):377-382
Chronic obstructive pulmonary dis-ease(COPD)is the most common chronic airway disease.The current status of treatment based mainly on bronchodilators and ICS is not sufficient for all of COPD patients.Various studies have at-tempted to use biologics targeting specific cyto-kines and their receptors in COPD patients to allevi-ate respiratory symptoms or reduce the risk of acute exacerbations.However,they failed to bring significant clinical benefits.More studies are need-ed to further determine the efficacy of targeted biotherapy for COPD.
2.Use of central neuromodulators in chronic cough
Bingxian SHA ; Haodong BAI ; Wanzhen LI ; Li YU ; Xianghuai XU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):432-439
Chronic cough is a common condition that imposes significant physical,psychological,and social burdens on patients.Although chronic cough is often associated with underlying condi-tions such as asthma,gastroesophageal reflux dis-ease,and eosinophilic bronchitis,some patients ex-perience uncontrollable coughing that is difficult to attribute to a specific cause.Many of these pa-tients exhibit clinical features of cough hypersensi-tivity syndrome,providing new directions for re-search into the treatment of chronic cough.As the pathophysiological mechanisms of chronic cough are further elucidated,treatment approaches for chronic cough are entering a new stage of develop-ment.This article summarizes and discusses the mechanisms and clinical evidence of central neuro-modulators used in the treatment of chronic cough,suggesting promising clinical applications for these drugs in the future.
3.Targeted biotherapy for chronic obstructive pulmonary disease
Haodong BAI ; Bingxian SHA ; Yadav Kumar AMBEDKAR ; Xianghuai XU ; Li YU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):377-382
Chronic obstructive pulmonary dis-ease(COPD)is the most common chronic airway disease.The current status of treatment based mainly on bronchodilators and ICS is not sufficient for all of COPD patients.Various studies have at-tempted to use biologics targeting specific cyto-kines and their receptors in COPD patients to allevi-ate respiratory symptoms or reduce the risk of acute exacerbations.However,they failed to bring significant clinical benefits.More studies are need-ed to further determine the efficacy of targeted biotherapy for COPD.
4.Use of central neuromodulators in chronic cough
Bingxian SHA ; Haodong BAI ; Wanzhen LI ; Li YU ; Xianghuai XU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):432-439
Chronic cough is a common condition that imposes significant physical,psychological,and social burdens on patients.Although chronic cough is often associated with underlying condi-tions such as asthma,gastroesophageal reflux dis-ease,and eosinophilic bronchitis,some patients ex-perience uncontrollable coughing that is difficult to attribute to a specific cause.Many of these pa-tients exhibit clinical features of cough hypersensi-tivity syndrome,providing new directions for re-search into the treatment of chronic cough.As the pathophysiological mechanisms of chronic cough are further elucidated,treatment approaches for chronic cough are entering a new stage of develop-ment.This article summarizes and discusses the mechanisms and clinical evidence of central neuro-modulators used in the treatment of chronic cough,suggesting promising clinical applications for these drugs in the future.
5.Targeted biotherapy for chronic obstructive pulmonary disease
Haodong BAI ; Bingxian SHA ; Yadav Kumar AMBEDKAR ; Xianghuai XU ; Li YU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):377-382
Chronic obstructive pulmonary dis-ease(COPD)is the most common chronic airway disease.The current status of treatment based mainly on bronchodilators and ICS is not sufficient for all of COPD patients.Various studies have at-tempted to use biologics targeting specific cyto-kines and their receptors in COPD patients to allevi-ate respiratory symptoms or reduce the risk of acute exacerbations.However,they failed to bring significant clinical benefits.More studies are need-ed to further determine the efficacy of targeted biotherapy for COPD.
6.Use of central neuromodulators in chronic cough
Bingxian SHA ; Haodong BAI ; Wanzhen LI ; Li YU ; Xianghuai XU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):432-439
Chronic cough is a common condition that imposes significant physical,psychological,and social burdens on patients.Although chronic cough is often associated with underlying condi-tions such as asthma,gastroesophageal reflux dis-ease,and eosinophilic bronchitis,some patients ex-perience uncontrollable coughing that is difficult to attribute to a specific cause.Many of these pa-tients exhibit clinical features of cough hypersensi-tivity syndrome,providing new directions for re-search into the treatment of chronic cough.As the pathophysiological mechanisms of chronic cough are further elucidated,treatment approaches for chronic cough are entering a new stage of develop-ment.This article summarizes and discusses the mechanisms and clinical evidence of central neuro-modulators used in the treatment of chronic cough,suggesting promising clinical applications for these drugs in the future.
7.Targeted biotherapy for chronic obstructive pulmonary disease
Haodong BAI ; Bingxian SHA ; Yadav Kumar AMBEDKAR ; Xianghuai XU ; Li YU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):377-382
Chronic obstructive pulmonary dis-ease(COPD)is the most common chronic airway disease.The current status of treatment based mainly on bronchodilators and ICS is not sufficient for all of COPD patients.Various studies have at-tempted to use biologics targeting specific cyto-kines and their receptors in COPD patients to allevi-ate respiratory symptoms or reduce the risk of acute exacerbations.However,they failed to bring significant clinical benefits.More studies are need-ed to further determine the efficacy of targeted biotherapy for COPD.
8.Use of central neuromodulators in chronic cough
Bingxian SHA ; Haodong BAI ; Wanzhen LI ; Li YU ; Xianghuai XU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):432-439
Chronic cough is a common condition that imposes significant physical,psychological,and social burdens on patients.Although chronic cough is often associated with underlying condi-tions such as asthma,gastroesophageal reflux dis-ease,and eosinophilic bronchitis,some patients ex-perience uncontrollable coughing that is difficult to attribute to a specific cause.Many of these pa-tients exhibit clinical features of cough hypersensi-tivity syndrome,providing new directions for re-search into the treatment of chronic cough.As the pathophysiological mechanisms of chronic cough are further elucidated,treatment approaches for chronic cough are entering a new stage of develop-ment.This article summarizes and discusses the mechanisms and clinical evidence of central neuro-modulators used in the treatment of chronic cough,suggesting promising clinical applications for these drugs in the future.
9.Targeted biotherapy for chronic obstructive pulmonary disease
Haodong BAI ; Bingxian SHA ; Yadav Kumar AMBEDKAR ; Xianghuai XU ; Li YU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):377-382
Chronic obstructive pulmonary dis-ease(COPD)is the most common chronic airway disease.The current status of treatment based mainly on bronchodilators and ICS is not sufficient for all of COPD patients.Various studies have at-tempted to use biologics targeting specific cyto-kines and their receptors in COPD patients to allevi-ate respiratory symptoms or reduce the risk of acute exacerbations.However,they failed to bring significant clinical benefits.More studies are need-ed to further determine the efficacy of targeted biotherapy for COPD.
10.Use of central neuromodulators in chronic cough
Bingxian SHA ; Haodong BAI ; Wanzhen LI ; Li YU ; Xianghuai XU
Chinese Journal of Clinical Pharmacology and Therapeutics 2024;29(4):432-439
Chronic cough is a common condition that imposes significant physical,psychological,and social burdens on patients.Although chronic cough is often associated with underlying condi-tions such as asthma,gastroesophageal reflux dis-ease,and eosinophilic bronchitis,some patients ex-perience uncontrollable coughing that is difficult to attribute to a specific cause.Many of these pa-tients exhibit clinical features of cough hypersensi-tivity syndrome,providing new directions for re-search into the treatment of chronic cough.As the pathophysiological mechanisms of chronic cough are further elucidated,treatment approaches for chronic cough are entering a new stage of develop-ment.This article summarizes and discusses the mechanisms and clinical evidence of central neuro-modulators used in the treatment of chronic cough,suggesting promising clinical applications for these drugs in the future.